乌鸦传媒

Jump to Main Content

Standing Committees

Subcommittee on Clinical Trials

Committee Roster

Chair
Grzegorz 聽S.聽Nowakowski,聽MD 聽('24)

Vice Chair
Stephanie Valer聽Seremetis,聽MD 聽('24)

Appointed Members
Uma聽Borate,聽MD 聽('26)
Donna聽DiMichele,聽MD 聽('26)
Martin 聽H.聽Dreyling,聽MD 聽('25)
Nahed聽El Kassar,聽MD, PhD 聽('25)
Jonathan聽Friedberg,聽MD 聽('25)
Irene 聽M.聽Ghobrial,聽MD 聽('25)
Neil聽Goldenberg,聽MD, PhD 聽('26)
Nicole 聽J.聽Gormley,聽MD 聽('25)
Alex 聽Francisco聽Herrera,聽MD 聽('26)
Fangxin聽Hong,聽PhD 聽('25)
Richard 聽F.聽Little,聽MD, MPH 聽('26)
Alan 聽E.聽Mast,聽MD, PhD 聽('25)
Lilli聽Petruzzelli,聽MD, PhD 聽('25)
Elna聽Saah,聽MD 聽('25)
George 聽A.聽Tomlinson,聽PhD 聽('25)
Jeffrey 聽I.聽Weitz,聽MD, FRCPC 聽('26)

Staff Liaison
础濒颈肠别听碍耻补产补苍,听惭厂

Committee Mandate

As the need for more personalized therapies for hematologic diseases increases, effective collaboration between academic investigators, biopharmaceutical companies, and federal agencies is critical to (1) address existing challenges in the clinical trial design process and (2) identify new strategies that will enhance and accelerate drug development.

 

The Subcommittee on Clinical Trials, a subcommittee of the Committee on Scientific Affairs, identifies prominent barriers to the design of clinical trials for hematologic diseases, determines ways ASH could play a role in overcoming such barriers, and if appropriate, makes recommendations to the Society. Specifically, the subcommittee has the following goals and priorities:

 

         Increase innovation and impact in hematology clinical trial design

         Enhance access and enrollment into hematology clinical trials (especially for underrepresented populations)

         Make hematology clinical trials easier to execute

         Increase education for hematologists, patients, and other healthcare providers to raise awareness about innovative clinical trial approaches in hematology

         Create pathways for lifelong learning in clinical trial methods and design

         Improve methodological aspects of innovative clinical trial design

         Disseminate innovative approaches in clinical research from other fields

         Develop strategies to improve access and enrollment to hematology clinical trials for underrepresented populations (e.g., patient engagement, regulatory burden, cultural barriers)

         Interface more with the US Food and Drug Administration, as well as other domestic and international regulatory agencies to discuss and help disseminate regulatory guidelines related to hematology clinical trials, real world evidence, and COVID-19

 

Members of the Subcommittee on Clinical Trials are appointed to three-year staggered terms (with the possibility of renewal once) and include experts from various stakeholder groups (i.e., academia, industry, regulatory agencies). The chair and vice chair each serve two-year terms. If not already a member of the Committee on Scientific Affairs, the chair of the Subcommittee on Clinical Trials serves as a liaison to the Committee on Scientific Affairs. The subcommittee鈥檚 leadership always represents both malignant and classical hematology.

 

Members of the Subcommittee on Clinical Trials are required to participate in regularly scheduled conference calls and one in-person meeting if deemed necessary.

...